Multiple myeloma etiology and treatment

Abstract

Genomic aberrations comprise hallmarks of multiple myeloma (MM), a plasma cell malignancy with an overall poor prognosis. MM is heterogeneous and has different molecularly-defined subtypes according to varying clinical and pathological features. Hyperdiploidy or non-hyperdiploidy has usually been identified as early initiating genetic events that can be followed by secondary aberrations, including copy number changes, secondary translocations, and different epigenetic modifications, which cause immortalization of plasma cell and disease progression. Even though recent advances in drug discovery have offered new perspectives of treatment, MM remains incurable. However, understanding the molecular complexity of MM would allow patients to get precision treatment. Our review focuses on current evidence in myeloma biology with special attention to genomic and molecular variations.

Keywords

Multiple myeloma / cancer genetics / targeted therapy / clinical trial

References

[1] ManierS,ParkJ,GetzG.Genomic complexity of multiple myeloma and its clinical implications.Nat Rev Clin Oncol2017;14:100-13

[2] TalleyPJ,BuckleCH.Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.Br Med Bull2015;113:15-30

[3] JanzS,SunF.Germline risk contribution to genomic instability in multiple myeloma.Front Genet2019;10:424 PMCID:PMC6518313

[4] LiyanageM,du ManoirS.Multicolour spectral karyotyping of mouse chromosomes.Nat Genet1996;14:312-5

[5] GradeM,CampsJ.Patterns of Chromosomal Aberrations in Solid Tumors.Recent Results Cancer Res2015;200:115-42 PMCID:PMC4729311

[6] BahrGF.The fibrous structure of human chromosomes in relation to rearrangements and aberrations; a theoretical consideration.Fed Proc1975;34:2209-17

[7] ChapmanMA,KeatsJJ.Initial genome sequencing and analysis of multiple myeloma.Nature2011;471:467-72 PMCID:PMC3560292

[8] RaffanE.Next generation sequencing--implications for clinical practice.Br Med Bull2011;99:53-71

[9] WentM,SudA.Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.Hum Genomics2019;13:37 PMCID:PMC6700979

[10] van LaarR,BrownN.Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.BMC Med Genomics2014;7:25 PMCID:PMC4032347

[11] SamoAA,ZhouM.MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.Genes Chromosomes Cancer2018;57:420-9

[12] KuehlWM.Early genetic events provide the basis for a clinical classification of multiple myeloma.Hematology Am Soc Hematol Educ Program2005;346-52:

[13] BergsagelPL.Molecular pathogenesis and a consequent classification of multiple myeloma.J Clin Oncol2005;23:6333-8

[14] PrideauxSM,ChevassutTJ.The genetic architecture of multiple myeloma.Adv Hematol2014;2014:864058 PMCID:PMC3996928

[15] BergsagelPL,ZhanF,BarlogieB.Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.Blood2005;106:296-303 PMCID:PMC1895118

[16] Clay-GilmourAI,BrownEE.Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance.Blood Adv2020;4:2789-97 PMCID:PMC7322948

[17] KristinssonSY,GoldinLR.Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.Int J Cancer2009;125:2147-50 PMCID:PMC2737604

[18] AltieriA,BermejoJL,HemminkiK.Familial risks and temporal incidence trends of multiple myeloma.Eur J Cancer2006;42:1661-70

[19] VachonCM,TherneauTM.Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.Blood2009;114:785-90 PMCID:PMC2716020

[20] MorganGJ,WeinholdN.Inherited genetic susceptibility to multiple myeloma.Leukemia2014;28:518-24

[21] BroderickP,JohnsonDC.Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk.Nat Genet2011;44:58-61 PMCID:PMC5108406

[22] KouraDT.Inherited predisposition to multiple myeloma.Ther Adv Hematol2013;4:291-7 PMCID:PMC3734900

[23] ChubbD,BroderickP.Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.Nat Genet2013;45:1221-5 PMCID:PMC5053356

[24] MartinoA,JamroziakK.Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma.Br J Haematol2012;158:805-9

[25] WeinholdN,RawstronAC.Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.Blood2014;123:2513-7; quiz 2593

[26] ZivE,HuD.Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Nat Commun2015;6:7539 PMCID:PMC4656791

[27] MitchellJS,WeinholdN.Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.Nat Commun2016;7:12050 PMCID:PMC4932178

[28] WentM,FörstiA.PRACTICAL consortiumIdentification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.Nat Commun2018;9:3707 PMCID:PMC6137048

[29] Duran-LozanoL,Lopez de Lapuente PortillaA.Germline variants at SOHLH2 influence multiple myeloma risk.Blood Cancer J2021;11:76 PMCID:PMC8055668

[30] LandgrenO.Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis.Leukemia2009;23:1691-7

[31] GreenbergAJ,RajkumarSV.Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.Leukemia2012;26:609-14 PMCID:PMC3629947

[32] CostaLJ,OmelJ,KumarSK.Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.Blood Adv2017;1:282-7 PMCID:PMC5727774

[33] WaxmanAJ,DevesaSS.Racial disparities in incidence and outcome in multiple myeloma: a population-based study.Blood2010;116:5501-6 PMCID:PMC3031400

[34] DuZ,SongGC.A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.Blood Adv2020;4:181-90 PMCID:PMC6960456

[35] CozenW,ContiDV.Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma.Cancer Epidemiol Biomarkers Prev2006;15:2285-91

[36] WeinholdN,JohnsonDC.The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.Haematologica2015;100:e110-3 PMCID:PMC4349291

[37] LiN,WeinholdN.Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.Nat Commun2016;7:13656 PMCID:PMC5123067

[38] BaughnLB,LarsonD.Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry.Blood Cancer J2018;8:96 PMCID:PMC6180134

[39] KeatsJJ,MaxwellCA.In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.Blood2003;101:1520-9

[40] ChangH,LiD.The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.Br J Haematol2004;125:64-8

[41] SantraM,TianE,ShaughnessyJ Jr.A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.Blood2003;101:2374-6

[42] KeatsJJ,TaylorBJ.Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.Blood2005;105:4060-9 PMCID:PMC1895072

[43] CappellenD,RicolD.Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.Nat Genet1999;23:18-20

[44] PeiH,LuoK.MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.Nature2011;470:124-8 PMCID:PMC3064261

[45] Avet-LoiseauH,RousselM.Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).J Clin Oncol2010;28:4630-4

[46] ShaughnessyJ Jr,QiY.Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.Blood2001;98:217-23

[47] ZhanF,CollaS.The molecular classification of multiple myeloma.Blood2006;108:2020-8 PMCID:PMC1895543

[48] MaoX,WoodTE.A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.Blood2011;117:1986-97

[49] Avet-LoiseauH,CampionL.Intergroupe Francophone du MyélomeTranslocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?.Blood2011;117:2009-11

[50] HurtEM,RosenwaldA.Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.Cancer Cell2004;5:191-9

[51] WalkerBA,MurisonA.APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.Nat Commun2015;6:6997 PMCID:PMC4568299

[52] RossFM,DagradaG.UK Myeloma ForumThe t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.Haematologica2010;95:1221-5 PMCID:PMC2895050

[53] SolvasonN,KabraN,LeesE.Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes.J Exp Med1996;184:407-17 PMCID:PMC2192735

[54] WalkerBA,WardellCP.Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma.J Clin Oncol2015;33:3911-20 PMCID:PMC6485456

[55] Avet-LoiseauH,MagrangeasF,HarousseauJL.Intergroupe Francophone du MyélomeRearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.Blood2001;98:3082-6

[56] DibA,GlebovOK,KuehlWM.Characterization of MYC translocations in multiple myeloma cell lines.J Natl Cancer Inst Monogr2008;(39):25-31 PMCID:PMC2737184

[57] WalkerBA,ChiecchioL.A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.Blood2010;116:e56-65

[58] Debes-MarunCS,BryantS.Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.Leukemia2003;17:427-36

[59] ChngWJ,AhmannGJ.A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.Blood2005;106:2156-61 PMCID:PMC1895145

[60] OnoderaN,RubinC.Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia [see comments].Blood1992;80:203-8

[61] ChngWJ,VanwierS.Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.Cancer Res2007;67:2982-9

[62] SmadjaNV,BrigaudeauC,FruchartC.Groupe Français de Cytogénétique HématologiqueHypodiploidy is a major prognostic factor in multiple myeloma.Blood2001;98:2229-38

[63] ChretienML,Lauwers-CancesV.Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?.Blood2015;126:2713-9 PMCID:PMC4683332

[64] PawlynC,MurisonA.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.Blood2015;125:831-40

[65] SawyerJR,HeuckCJ.Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.Blood2014;123:2504-12 PMCID:PMC3990913

[66] SchmidtTM,JosephN.Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.Blood Cancer J2019;9:94 PMCID:PMC6877577

[67] LiC,DarbroB.Genetic Analysis of multiple myeloma identifies cytogenetic alterations implicated in disease complexity and progression.Cancers (Basel)2021;13:517 PMCID:PMC7866300

[68] BoydKD,WalkerBA.NCRI Haematology Oncology Studies GroupMapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.Clin Cancer Res2011;17:7776-84 PMCID:PMC5751883

[69] FonsecaR,DrachJ.International Myeloma Working GroupInternational Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Leukemia2009;23:2210-21 PMCID:PMC2964268

[70] TricotG,JagannathS.Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.Blood1995;86:4250-6

[71] LodéL,TrichetV.Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.Haematologica2010;95:1973-6 PMCID:PMC2966923

[72] DrachJ,FritzE.Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.Blood1998;92:802-9

[73] Avet-LoiseauH,MoreauP.Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.Blood2007;109:3489-95

[74] GmidèneA,Avet-LoiseauH.8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.Med Oncol2013;30:489

[75] PrattG.Molecular aspects of multiple myeloma.Mol Pathol2002;55:273-83 PMCID:PMC1187254

[76] OeckinghausA.The NF-kappaB family of transcription factors and its regulation.Cold Spring Harb Perspect Biol2009;1:a000034 PMCID:PMC2773619

[77] AnnunziataCM,DemchenkoY.Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.Cancer Cell2007;12:115-30 PMCID:PMC2730509

[78] KeatsJJ,ChesiM.Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.Cancer Cell2007;12:131-44 PMCID:PMC2083698

[79] ZhangW.MAPK signal pathways in the regulation of cell proliferation in mammalian cells.Cell Res2002;12:9-18

[80] ChngWJ,Price-TroskaT.Clinical and biological significance of RAS mutations in multiple myeloma.Leukemia2008;22:2280-4 PMCID:PMC3864109

[81] PatrawalaS.Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.Future Oncol2012;8:509-23

[82] BhartiAC,ReubenJM.Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.Blood2004;103:3175-84

[83] KawanoM,MatsudaT.Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.Nature1988;332:83-5

[84] De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.Br J Haematol2000;109:823-8

[85] AlasS.Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.Clin Cancer Res2003;9:316-26

[86] OsakiM,ItoH.PI3K-Akt pathway: its functions and alterations in human cancer.Apoptosis2004;9:667-76

[87] AronsonLI,GiuntoliSG.Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis.Blood2010;116:4083

[88] TasakaT,VescioR.Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma.Br J Haematol1997;96:98-102

[89] UchidaT,OhnoT,NagaiH.Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia.Leukemia2001;15:157-65

[90] KassambaraA,SahotaS.A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.Oncotarget2014;5:2487-98 PMCID:PMC4058021

[91] NeriP,GrattonK.Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.Blood2011;118:6368-79 PMCID:PMC4348156

[92] HuY,FangH.Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.Leukemia2018;32:2250-62 PMCID:PMC6151178

[93] PerrotA,CorreJ.Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.Blood2018;132:2456-64 PMCID:PMC6284215

[94] MarchesiniM,CollaS.RNA processing: a new player of genomic instability in multiple myeloma.Oncoscience2017;4:73-4 PMCID:PMC5616198

[95] FucciC,RivaE.The interaction of the tumor suppressor FAM46C with p62 and FNDC3 proteins integrates protein and secretory homeostasis.Cell Rep2020;32:108162

[96] CollaS,OgotiY.Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.Cancer Cell2015;27:644-57 PMCID:PMC4596059

[97] PereiraB,AlmeidaR.RNA-binding proteins in cancer: old players and new actors.Trends Cancer2017;3:506-28

[98] MarchesiniM,FioriniE.ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma.Cancer Cell2017;32:88-100.e6 PMCID:PMC5593798

[99] ShafferAL,LamyL.IRF4 addiction in multiple myeloma.Nature2008;454:226-31 PMCID:PMC2542904

[100] GreenbergAJ,KumarSK,JelinekDF.Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.Eur J Haematol2013;91:504-13 PMCID:PMC3834223

[101] SchusterSR,ZhuYX.The clinical significance of cereblon expression in multiple myeloma.Leuk Res2014;38:23-8 PMCID:PMC3905958

[102] MandelbaumJ,TangH.BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.Cancer Cell2010;18:568-79 PMCID:PMC3030476

[103] EsteveFR.Pathophysiology of myeloma bone disease.Best Pract Res Clin Haematol2007;20:613-24

[104] TianE,WalkerR.The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.N Engl J Med2003;349:2483-94

[105] QiangYW,StephensO.Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.Blood2008;112:196-207 PMCID:PMC2435688

[106] FulcinitiM,HideshimaT.Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.Blood2009;114:371-9 PMCID:PMC2714212

[107] CeaM,AdamiaS.Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.Blood2016;127:1138-50 PMCID:PMC4778164

[108] SongY,RayA.Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Oncogene2017;36:5631-8 PMCID:PMC5705032

[109] QinY,DengS.Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma.Leukemia2017;31:1123-35

[110] CaraccioloD,AmodioN.miR-22 suppresses DNA ligase III addiction in multiple myeloma.Leukemia2019;33:487-98 PMCID:PMC6365379

[111] WalkerBA,ChiecchioL.Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.Blood2011;117:553-62

[112] TricotG.New insights into role of microenvironment in multiple myeloma.Lancet2000;355:248-50

[113] KleinB,LuZ.Interleukin-6 in human multiple myeloma.Blood1995;85:863-72

[114] ZhanF,KordsmeierB.Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.Blood2002;99:1745-57

[115] HazlehurstLA,BuyuksalI,DaltonWS.Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).Oncogene2000;19:4319-27

[116] MohtyM.Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.Haematologica2014;99:408-16 PMCID:PMC3943303

[117] HideshimaT,RichardsonPG.A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.Ther Clin Risk Manag2008;4:129-36 PMCID:PMC2503648

[118] WeberDM,NiesvizkyR.Multiple Myeloma (009) Study InvestigatorsLenalidomide plus dexamethasone for relapsed multiple myeloma in North America.N Engl J Med2007;357:2133-42

[119] AbramsonHN.Monoclonal antibodies for the treatment of multiple myeloma: an update.Int J Mol Sci2018;19:3924 PMCID:PMC6321340

[120] ItoS.Proteasome inhibitors for the treatment of multiple myeloma.Cancers (Basel)2020;12:265 PMCID:PMC7072336

[121] MikhaelJ.Treatment options for triple-class refractory multiple myeloma.Clin Lymphoma Myeloma Leuk2020;20:1-7

[122] GandhiUH,LakshmanA.Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.Leukemia2019;33:2266-75 PMCID:PMC6820050

[123] GerrieAS,ChengL.D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.Br J Haematol2013;161:802-10

[124] GriffinPT,FulpW.A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.Cancer2015;121:3622-30

[125] MichaelM,BölkeE.Bendamustine in patients with relapsed or refractory multiple myeloma.Eur J Med Res2010;15:13-9 PMCID:PMC3351842

[126] LauIJ,AitchisonR.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Ann Hematol2015;94:643-9

[127] LudwigH,LeitgebC.Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.Blood2014;123:985-91 PMCID:PMC3924931

[128] San-miguelJF,YoonS.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.Lancet Oncol2014;15:1195-206

[129] RichardsonPG,AlsinaM.PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.Blood2013;122:2331-7

[130] SiegelDS,JagannathS.VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma.Clin Lymphoma Myeloma Leuk2016;16:329-34.e1

[131] DimopoulosM,LonialS.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.Lancet Oncol2013;14:1129-40

[132] AttalM,HulinC.IFM 2009 StudyLenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med2017;376:1311-20 PMCID:PMC6201242

[133] RichterJ,RichardS.Selinexor in relapsed/refractory multiple myeloma.Ther Adv Hematol2020;11:2040620720930629 PMCID:PMC7285937

[134] LinQ,SongY.Recent updates on CAR T clinical trials for multiple myeloma.Mol Cancer2019;18:154 PMCID:PMC6829852

[135] YuB,LiuD.BCMA-targeted immunotherapy for multiple myeloma.J Hematol Oncol2020;13:125 PMCID:PMC7499842

[136] JännePA,PereiraJR.Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.Lancet Oncol2013;14:38-47

[137] Abdel-WahabO,GaskellAA.Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.Cancer Discov2014;4:538-45 PMCID:PMC4850735

[138] PunnooseEA,PealeF.Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models.Mol Cancer Ther2016;15:1132-44

[139] FilippakopoulosP,PicaudS.Selective inhibition of BET bromodomains.Nature2010;468:1067-73 PMCID:PMC3010259

[140] GuagnanoV,WöhrleS.FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.Cancer Discov2012;2:1118-33

[141] GavinePR,KilgourE.AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.Cancer Res2012;72:2045-56

[142] PawlynC.Toward personalized treatment in multiple myeloma based on molecular characteristics.Blood2019;133:660-75 PMCID:PMC6384187

[143] BaughnLB,WuK.A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.Cancer Res2006;66:7661-7

[144] JelinekT,HajekR.Update on PD-1/PD-L1 inhibitors in multiple myeloma.Front Immunol2018;9:2431 PMCID:PMC6250817